What Scaboral Treats: Main Uses and Benefits

Scaboral (Crotamiton) is a topical application used for managing symptoms related to parasitic infestation and other symptoms related to physical discomfort. It is applied when supportive symptom management is needed, and it is indicated for use as an antipruritic and sarcopticide. The medicine is commonly used to help with symptoms related to physical discomfort in situations involving certain distressing symptoms.

Easing Episodic Symptom Discomfort

Scaboral is primarily relevant in contexts marked by increased discomfort or tension, where symptoms may appear suddenly or intensify over time. This use is applicable across domains where additional symptomatic support is needed for uncomfortable skin sensations. It contributes to improved day-to-day comfort during periods of heightened symptoms, and may assist with easing symptoms that create noticeable physiological strain.

“Applied across domains where additional symptomatic support is needed.”

Supportive Relief for Acute Symptom Clusters

Scaboral is applied in addressing conditions involving parasitic infestation that present with disruptive symptom manifestations. It is relevant in conditions characterized by periods of heightened symptoms, where symptoms cluster into patterns requiring supportive management. The medication offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, providing supportive relief when symptoms interfere with routine activities. It is also used in the management of symptoms associated with conditions presenting with systemic or localized discomfort.

Quick Fact: May Assist with Managing Disruptive Symptom Manifestations

Regulatory References

1. HPRA Summary of Product Characteristics

Who Can and Cannot Use Scaboral?

Eligibility for Scaboral (Ivermectin) is strictly defined by official government regulatory documents.

Absolute Exclusions and Contraindications

The medicine is contraindicated for any patient with a known hypersensitivity to Ivermectin or to any other component of the product.

Use is generally not recommended during pregnancy and is considered an absolute restriction because safety in this patient population has not been established. For lactating mothers, use is conditional and must only be undertaken when the benefit to the mother outweighs the possible risk to the newborn.

Age and Weight Restrictions

Use is established for adults and children weighing 15 kilograms or more. Regulatory labeling states that safety and efficacy have not been established in children who weigh less than 15 kg; therefore, use is not permitted in this weight category. Caution is also advised for older adults due to the increased likelihood of age-related organ issues.

Conditional Use and Organ Function

Use is not established in patients with significant hepatic or renal impairment, as dedicated clinical studies were not performed. Patients living in Loa loa endemic areas who may have co-infection require clinical assessment prior to treatment due to the documented risk of serious neurological complications.

Interactions with other medicines and products

Official regulatory documents define the interaction profile for Scaboral (Ivermectin) through specific pharmacokinetic and pharmacodynamic constraints. No medicinal product combinations are formally classified as contraindicated in regulatory labeling; instead, interactions are noted as requiring monitoring and caution.

Interaction Scope

Official Interaction Statements

• Co-administration with strong CYP3A4 inhibitors reduces the clearance of Ivermectin, which is formally documented to increase Ivermectin plasma concentrations.
• The use of agents that inhibit P-glycoprotein may lead to higher systemic exposure due to reduced drug efflux.
• Combination with Warfarin has been associated with post-marketing reports of an increased International Normalized Ratio (INR), reflecting enhanced anticoagulant activity.
• Co-use with Alcohol may increase the risk of central nervous system (CNS) effects such as dizziness or sleepiness.
• The co-administration of other microfilaricidal drugs like DEC-C is associated with an increased risk of severe systemic reactions.

The regulatory documents define the product’s interaction structure primarily through constraints on metabolic and transport clearance, specifying agents that increase exposure. This structure also highlights pharmacodynamic concerns, such as the potential for enhanced anticoagulant effects and additive CNS effects.

Scaboral (Ivermectin) functions as an antiparasitic agent by selectively targeting the core nervous and muscular systems of invertebrates. The drug achieves its effect through a specific molecular mechanism that exploits a fundamental biological difference between parasites and the host. Its primary action involves highly specific binding and activation of glutamate-gated chloride channels ( GluCl), which are critical ion channels found almost exclusively in invertebrate nerve and muscle cells. Ivermectin acts as a direct, high-affinity agonist at these channels, initiating a sustained molecular cascade that overrides the parasite's normal inhibitory signaling pathways. Activation of GluCl channels leads to a massive, sustained influx of chloride ions ( Cl^-) across the parasite’s cell membranes. This process results in profound hyperpolarization, which prevents the transmission of electrical signals necessary for motor function. The physiological consequence is a complete flaccid paralysis of the parasite, halting its feeding and movement, which is the final step in the anthelmintic effect. This selective action is due to the absence of the primary molecular target ( GluCl channels) in mammals, and the presence of the human P-glycoprotein ( P-gp) transporter. This efflux pump actively restricts Ivermectin's limited ability to enter the host’s Central Nervous System (CNS) tissues. This dual selectivity contributes to confining the drug's action to the parasite's physiological systems.

Official Dosing and Administration for Scaboral (Ivermectin)

Scaboral, which contains the active ingredient Ivermectin, is an oral tablet for systemic use. The dosing regimen is weight-based, and administration is dictated by specific conditions to ensure proper systemic delivery.

Administration Instructions

Standard Dosing and Frequency

The dosage is typically a single oral dose for treatment, with specific weight-based amounts defined for different conditions:

• Strongyloidiasis (Threadworm): A single dose is calculated to provide approximately 200 micrograms / kg (0.2 mg/ kg) of body weight. Follow-up stool examinations are required to verify eradication.
• Onchocerciasis (River Blindness): A single dose is calculated to provide approximately 150 micrograms / kg (0.15 mg/ kg) of body weight. Retreatment is often required at intervals of 6 to 12 months for long-term microfilarial control.

Pediatric Patients: Safety and efficacy have only been established in children who weigh 15 kg or more. Dosing for eligible children follows the same weight-based calculation as for adults.

These administration guidelines ensure the medicine is used in a standardized manner, providing a clear protocol for the one-time or cyclical administration of the weight-dependent dose.

Research Evidence / Overview of Studies for Scaboral (Oral Ivermectin)

Scaboral (Ivermectin) was evaluated in research exploring certain parasitic conditions. The research available includes different types of trials, such as Randomized Controlled Trials (RCTs), large-scale community-based observational studies, and systematic reviews. Investigations primarily aimed to examine how the medicine was observed in different patient groups and what changes in infection or symptoms were measured during the study periods.

Evidence for Use in Intestinal Strongyloidiasis

Research has explored Scaboral’s role in patients with Strongyloides stercoralis infection using RCTs and comparative studies. Investigations measured the parasitological cure rate, which involves assessing the absence of larvae, and tracked how symptoms evolved in the observed populations. Findings describe patterns observed in the studies regarding measured rates of parasitological cure. Long-term effects are not fully established, and data remains insufficient for groups like immunocompromised patients.

Evidence for Use in Onchocerciasis (River Blindness)

The research base relies on large-scale community-based trials and observational programs in endemic areas. Studies monitored the reduction or clearance of microfilariae in the skin and eyes and the broader epidemiological impact on disease transmission. Comparative evidence against non-treatment controls is typically lacking for certain study designs where the use of a control group may be unethical.

Evidence for Use in Scabies

Research includes comparative RCTs against topical treatments, examining measured rates of parasitological cure and changes in patient-reported discomfort (itching). Findings were mixed across studies, and follow-up durations were limited, making it difficult to distinguish between persistent infection and residual post-scabietic symptoms.

Long-Term Research and Durability of Response

Studies monitored patients over defined time intervals to assess the durability of the observed response and measured rates of sustained parasitological cure. However, there is limited information available to fully characterize the long-term observed response years after initial or repeated treatment.

Research in Special Populations

Research was evaluated in specific patient groups, including children (above minimum weight) and immunocompromised patients. Data for pregnant individuals and other subgroups remain insufficient, and therefore, subgroup findings are uncertain for these specific groups.

Key Limitations and Areas of Uncertainty

The research surrounding Scaboral presents several known limitations. For all indications, long-term effects are not fully established, as follow-up durations were limited in many primary trials. For scabies, evidence quality varies across studies, and sample sizes were modest in some clinical trials.

Key Studies & References WHO guideline on preventive chemotherapy for public health control of strongyloidiasis (2023)

Common questions about Scaboral (FAQ)

Q: What is the main difference between Scaboral and other common treatments for the same condition?

Scaboral, which contains the active ingredient Ivermectin, is classified as a macrocyclic lactone anthelmintic. Official studies sometimes compare it to other antiparasitic agents, usually noting its unique mechanism of action or the efficacy observed with a single dose for certain conditions. This classification indicates its mechanism of action is distinct from some other drug classes.

Q: Is Scaboral considered a new or long-standing treatment?

According to official public health bodies, Scaboral (Ivermectin) is considered a long-standing antiparasitic treatment. It received approval for human use by government agencies starting in the late 1980s and is included on the World Health Organization's List of Essential Medicines.

Q: Does Scaboral work for all types of the condition it treats?

Studies and official product information indicate that Ivermectin's activity is selective. For example, its effectiveness against the common parasitic infection Strongyloides stercoralis is specifically limited to the intestinal stages of the parasite. This specific activity reflects the known action of the medicine.

Q: How quickly can I expect to notice Scaboral working?

The drug's mechanism of action is described as causing a rapid paralysis of the targeted parasites within the body. Clinical studies have measured a reduction in parasite load over time. However, official documents do not define an exact time frame for when subjective symptomatic improvement may be noticed, as this can vary.

Q: What happens if I forget to take Scaboral?

Since Scaboral is often prescribed as a single, weight-dependent dose, a missed dose may require specific advice from the prescriber. For repeat-dose treatments, official patient leaflets generally advise taking the missed dose as soon as remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose should be skipped. It is generally advised not to take a double dose to make up for a missed one.

Q: Are there any specific organs or body systems that Scaboral is known to affect?

Official information indicates Scaboral is primarily processed by the liver and excreted through the feces. Reported adverse effects frequently involve the nervous system (such as dizziness or headache), the gastrointestinal system, and the skin (itching, rash).

Q: Do the side effects of Scaboral usually go away over time?

Regulatory documents state that most side effects are generally mild or moderate in intensity and tend to resolve on their own. For example, specific immune-related reactions known as Mazzotti-type reactions are noted to typically appear and resolve within the first few days following initial treatment.

Q: Does Scaboral interact with common pain relievers like ibuprofen or aspirin?

Official drug labels do not specifically list common over-the-counter pain relievers like ibuprofen or aspirin as formal drug interactions. However, Ivermectin has been associated with an increased anticoagulant effect when co-administered with Warfarin, a medicine that also affects blood clotting.

Q: Are there any ongoing clinical trials for Scaboral?

Public databases maintained by government entities, such as ClinicalTrials.gov, list studies that have been conducted or are ongoing to further evaluate the use of Ivermectin. These investigations are for the purpose of further evaluation.

Q: Is Scaboral a controlled substance or scheduled drug?

According to official regulatory bodies, Scaboral (Ivermectin) is not listed as a controlled substance or scheduled drug under the U.S. Controlled Substances Act.

Q: Is Scaboral available as a generic medicine?

Yes, official drug registries, such as the FDA's Approved Drug Products list (Orange Book), confirm that generic versions of the brand-name product are available containing the active ingredient Ivermectin.

Q: Does Scaboral have any effect on blood pressure?

Official adverse reaction reports have included instances of low blood pressure (hypotension) as a possible effect. This may sometimes lead to symptoms such as dizziness or lightheadedness, particularly when changing position from sitting or lying down.

Q: Are there different strengths or formulations of Scaboral?

Official regulatory documents indicate that oral tablets of Ivermectin (Scaboral) are officially available in multiple strengths. These commonly include tablets of 3 mg and 6 mg.

Q: Can Scaboral affect the results of lab tests?

Yes, the official product information notes that changes in liver enzyme levels have been documented as a side effect. Additionally, the medicine has been associated with an increase in the International Normalized Ratio (INR) in patients taking Warfarin, which reflects altered blood clotting test results.

Q: Is it common for Scaboral to be used alongside other therapies?

Scaboral (Ivermectin) is sometimes administered in combination with other anthelmintic agents (drugs that treat parasitic worms) as part of a combination regimen. Official warnings exist regarding co-administration with other microfilaricidal drugs.

Q: What happens to the body if someone takes too much Scaboral?

Clinical toxicology reports indicate that symptoms of acute overdose can include headache, dizziness, nausea, vomiting, abdominal pain, and extreme sleepiness. More severe toxicity has been linked to neurological issues like seizures and coma. The approach to management focuses on monitoring and support.

Q: Is there a known antidote for an overdose of Scaboral?

Official toxicology and poison control information states that there is no specific antidote for an overdose of Ivermectin. In the event of an overdose, treatment focuses on monitoring and managing the specific symptoms that occur.

Q: Can Scaboral cause any changes in mood or behavior?

Adverse effects involving the nervous system have been reported in official documents, including confusion, disorientation, and extreme sleepiness. These are classified as neurological problems that can affect a person's state of mind and behavior.

Q: How long does Scaboral stay in your system after stopping treatment?

Official pharmacokinetic data indicates that the drug has a plasma half-life of approximately 18 hours in humans. The medicine and its breakdown products (metabolites) are generally excreted slowly, with most cleared almost entirely in the feces over an estimated 12 days.

Q: Are there patient assistance programs available for Scaboral?

Yes, official manufacturer patient assistance programs (PAPs) have been established to help certain patients access the medicine. These programs are designed to provide the medicine free of charge to eligible individuals who are uninsured and meet specific financial and medical hardship criteria.

How to Store and Dispose of Scaboral

Scaboral (Ivermectin) tablets must be stored according to specific regulatory requirements to maintain product stability and ensure safety.

Storage Requirements

• Temperature Control: Store the medicine at room temperature and below 30 C (86 F). It is essential not to freeze the tablets.
• Environmental Protection: Keep Scaboral in its original container to protect it from light and moisture.
• Child Safety: Always store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Scaboral should not be flushed down the toilet or disposed of in wastewater due to its documented environmental toxicity, especially to aquatic life. All unused product must be discarded in accordance with local regulations for pharmaceutical waste, often requiring return to a pharmacy or a designated disposal site.